BriaCell Therapeutics Corp. CEO William V. Williams, MD, FACP, discussed the path to personalized scalable solid tumor immunotherapies in a guest column for Drug Discovery Online.
Public source
Publisher name
Public post
In a guest column for Drug Discovery Online, BriaCell CEO William V. Williams, MD, FACP, discusses the path to personalized scalable solid tumor immunotherapies. Read th…
Company
BriaCell Therapeutics Corp.
Developing Novel Therapies to Destroy Cancer
- Industry
- Biotechnology Research
- Location
- Philadelphia, US
- Company size
- 11–50 employees
About BriaCell Therapeutics Corp.
BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) is a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care. More information is available at https://briacell.com/.
See moreLatest activity
Latest activity from BriaCell Therapeutics Corp.
12 signals
Research & Knowledge
BriaCell Therapeutics Corp. welcomed MSK as a clinical site in its Phase 3 study for metastatic breast cancer.
Research & Knowledge
BriaCell Therapeutics Corp. announced that Memorial Sloan Kettering Cancer Center (MSK) joined BriaCell's ongoing pivotal Phase 3 study of Bria-IMT plus an immune checkpoint inhibitor in metastatic breast cancer.
People
BriaCell Therapeutics Corp. is hiring a Scientist/Senior Scientist in the Quality Control department in Philadelphia, USA.
Discover more
Similar signals
Similar public activity from other companies.
Research & Knowledge
Calidi Biotherapeutics
Calidi Biotherapeutics CEO Eric Poma, Ph.D., shared his perspective on targeted immune activation, drug delivery, and tumor microenvironment therapeutic activity in a new article published in Morgan Kohler's Drug Discovery Online.
Research & Knowledge
Dendreon
Dendreon published a review exploring years of clinical and real-world experience about personalized cellular immunotherapy in advanced prostate cancer.
Research & Knowledge
Nouscom
Nouscom published Phase 1b/2 data in NatureMedicine.
Research & Knowledge
Guidant BioTherapeutics
Guidant BioTherapeutics is applying the biology of IL-12 and IL-18 through GDT 003 and the FHAB platform to treat cold tumors.
Research & Knowledge
ImmunityBio, Inc.